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Abstract 
 
Background § aims: Cytochrome P450 1A1 (CYP1A1) catalyzes the degradation of 
endobiotics (estradiol, fatty acids…) and the bioactivation of numerous environmental 
procarcinogens such as arylamines and polycyclic aromatic hydrocarbons that were 
found in food. Several peroxysome proliferators and arachidonic acid derivatives 
enhance CYP1A1 activity, but the mechanisms involved remain unknown. The aim of 
this work was to study the role of PPAR receptors in CYP1A1 gene induction.  
Methods: The role of PPAR transcription factors in CYP1A1 induction was assessed 
by means of Enzymatic activities, QRT-PCR, gene reporter assays, mutagenesis and 
EMSA.  
Results: We demonstrate that PPAR agonists (WY-14643, bezafibrate, clofibrate 
and phthalate) induce human CYP1A1 gene expression, while 2,4-thiazolidinedione, 
a specific PPAR agonist, represses it. The induction of CYP1A1 transcripts by 
WY-14643 was associated with a marked increase of EROD activity (10-fold at 200 
µM). Transfection of PPARcDNA enhanced CYP1A1 mRNA induction by 
WY-14643 although WY-14643 failed to activate XRE sequences. Two PPRE sites 
were located at the positions –931/-919 and –531/-519 of CYP1A1 promoter. Their 
inactivation by directed mutagenesis, suppressed the inductive effect of WY-14643 
on CYP1A1 promoter activation. EMSA and chromatin immunoprecipitation assay 
experiments demonstrated that the two CYP1A1 PPRE sites bind the PPAR/RXR 
heterodimer. 
Conclusions: We describe here a new CYP1A1 induction pathway involving PPAR 
and two PPRE sites indicating that PPAR ligands, which are common 
environmental compounds, may be involved in carcinogenesis. 
Introduction 
 
Cytochromes P450 (CYPs) are hemoproteins involved in the metabolism of 
some endogenous compounds (estradiol, fatty acids) and numerous xenobiotics. 
CYPs are the main enzymes involved in the bioactivation of environmental 
procarcinogens. CYP1A1 catalyzes the bioactivation of polycyclic aromatic 
hydrocarbons (PAHs) and arylamines. PAHs are ubiquitous compounds found in 
tobacco smoke, industrial workplace, and food. Arylamines are pyrolysis derivatives 
of proteins. PAHs and arylamines are mainly involved in the etiology of smokers’ lung 
cancers and colorectal cancers, respectively (1, 2). Moreover, CYP1A1 
overexpression was associated with predisposition to various human cancers (3). 
CYP1A1 is constitutively expressed in human enterocytes at relatively low 
level. However, it should be borne in mind that its expression is highly enhanced after 
exposition to chemical inducers, modulating cellular susceptibility to procarcinogens. 
CYP1A1 gene expression is mainly regulated by the Aryl hydrocarbon 
Receptor (AhR) which is activated by a variety of xenobiotic compounds including 
dioxins, PAHs (4-6), flavonoids, indole and benzimidazole derivatives (7-9). The AhR 
is present in cytoplasm as an inactive form associated with two hsp90 and another 
protein, named AIP, involved in the stability of the complex AhR-hsp90. The ligand 
binding on AhR induces the dissociation of this complex and activates the receptor. 
After its activation, AhR is able to translocate in the nucleus, where it dimerizes with 
its partner, the aryl hydrocarbon receptor nuclear translocator (Arnt). This new 
complex binds specifically to enhancer DNA sequences within the CYP1A1 promoter 
called XRE (Xenobiotic Responsive Element). 
In spite of the fact that AhR plays a central role in CYP1A1 gene regulation, 
the activation of this transcription factor cannot always explain the observed CYP1A1 
induction. For instance, carbaryl which is not an AhR ligand was found to induce 
CYP1A1 (10) by a mechanism not yet characterized. 
AhR excepted, the other transcription factor involved in CYP1A1 induction was 
RAR but the level of induction reached was relatively faint (11). 
It has been previously demonstrated that induction of CYP1A1 activity can be 
obtained by cell culture agitation, with a level comparable to those obtained with 
exposure to 0.1 nM TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxine) (12). Increasing 
shear stress leads to an increase of arachidonic acid level (13, 14) and arachidonic 
acid metabolites are PPAR ligands (15). Using arachidonic acid and different 
phospholipid metabolism inhibitors, Mufti et al. (12) demonstrated that arachidonic 
acid and derivatives induce CYP1A1 gene activity and that cell stress induces 
phospholipase D, resulting in the formation of phosphatidic acid which activates 
phospholipase A2, resulting in the release of arachidonic acid. The metabolism of 
arachidonic acid probably resulted in a metabolite that, by an as yet unknown 
mechanism, induced CYP1A1 (12). 
Moreover, it was demonstrated that peroxisome proliferators, such as 
phthalates, can increase the DNA adducts induced by the bioactivation of 
benzo(a)pyrene which is mainly catalyzed by CYP1A1 (16). The mechanism involved 
in this increase of DNA adducts was not characterized. So, phthalates appeared to 
be inducers of CYP1A1 activity. To date, it has been demonstrated that some 
phthalate derivatives are potent agonist ligands of PPAR and to a lesser extent of 
PPAR. We hypothesized that the potentiation of benzo(a)pyrene DNA adducts 
by phthalates could be related to CYP1A1 induction via the PPAR pathway. 
The aim of this study was to evaluate the effect of PPAR ligands such as 
WY-14643 (a specific PPAR -
ethylhexyl)phthalate (MEHP) or specific PPAR
(TZD) on CYP1A1 expression in CaCo-2 cells. We demonstrated that CYP1A1 is 
highly inducible by PPAR ligands. This induction specifically involves the 
transcription factor PPAR and requires 2 PPRE sites located within the CYP1A1 
promoter (positions –931/-919 and –531/-519). Our data characterize a new PPAR-
mediated CYP1A1 regulation pathway. This may be the basis of carcinogenesis by 
many environmental compounds acting as PPAR ligands. 
Materials and Methods 
 
Chemicals WY-14643 were purchased from VWR (France), 2-4, thiazolidinedione, 
3-methylcholanthrene (3-MC), clofibrate (CF), bezafibrate (BZF) and 
dimethylsulfoxide were purchased from SIGMA (France) and Mono(2-
ethylhexyl)phthalate (MEHP) from TCI Europe (Belgium). 
 
Cell culture and treatments Human colic adenocarcinoma CaCo-2, the hepatoma 
HepG2, the adenocarcinoma A549 cells and the primoculture of human keratinocytes 
were used. As soon as the CaCo-2 cells reached confluence, the culture medium 
was changed and 24 h later, they were further treated during 6 h with either the 
PPAR agonists such as WY-14643 (10, 30, 100, 200, and 400 µM). 100 µM MEHP, 
50 µM clofibrate, 50 µM bezafibrate or the PPAR agonist 2, 4-Thiazolidinedione 
(200 µM) or the AhR ligand 3-MC (1 µM). In the same conditions, HepG2, 
keratinocytes and A549 were treated with 200 µM of WY-14643 and 1 µM 3-MC. 3-
MC was used as control CYP1A1 inducer. 
 
QRT-PCR experiments Total RNA was isolated from cells using Nucleospin 
RNAII (Macherey Nagel, France). One µg of total RNA was reverse-transcribed in 
30 µl using GibcoBRL M-MLV reverse-transcriptase (Life Technologies, Cergy 
Pontoise, France) in its own buffer and random primers at 37°C for 1 h. CYP1A1 
mRNA expression normalized to β2-microglobulin expression was determined using 
the LightCycler System (RocheDiagnostic, France) and the Faststart DNA master 
SYBRGreen I Kit (Roche diagnostics). The primers for CYP1A1 and β2-microglobulin 
were as follow: 
CYP1A1-S: 5’AAGAGGAGCTAGACACAGT3’ 
 CYP1A1-AS: 5’GAAACCGTTCAGGTAGGA3’ 
 β2m-S: 5’CCGACATTGAAGTTGACTTAC3’ 
 β2m-AS: 5’ATCTTCAAACCTCCATGATG3’ 
PCR was performed with 5 mM MgCl2, 0.25 µM of each primer and LightCycler 
FastStart DNA Master SYBR Green I mix in a total volume of 16 µl. Cycling 
conditions were as follows: 10 min denaturation at 95°C, followed by 45 cycles of 10s 
denaturation at 95°C, 8 s primer annealing at 55°C and 8 s of fragment elongation at 
72°C. The melting curve was analyzed with the LightCycler software and quantitation 
was done with RelQuant software (Roche Diagnostic, France). 
Three independent experiments were at least realized in triplicate. 
 
EROD activity CaCo-2 cells were either untreated or treated with different 
concentrations of WY-14643 (10, 30, 100 and 200 µM). Ethoxyresorufin 
O-Deethylase (EROD) activity, mainly supported by CYP1A1, was determined 
according to the method of Burke et al. (18), slightly modified by Kennedy et al. (19). 
The fluorescence of resorufin produced during the reaction was measured using a 
CYTOFLUOR Multi-well plate reader series 400 (PerSeptive Biosystems) with 530 
nm excitation and 590 nm emission wavelengths. Fluorescence values were 
converted to picomoles using a calibration curve of resorufin fluorescence and EROD 
activity was expressed as pmol of resorufin/min/mg total cellular protein.  
 
Cloning of CYP1A1 XRE sequences Sense and antisense oligonucleotides 
containing two CYP1A1 XRE sites were synthesized with addition of Hind III and  
Xba I restriction sites at the 5’ and 3’ ends respectively. After hybridization and their 
digestion by Hind III and Xba I, these two oligonucleotides were cloned in the 
corresponding sites of the pBLCAT2 vector containing a thymidine kinase promoter 
(TK). This construction was named XRE-TK-CAT. The oligonucleotide sense used 
is :  
5’CCGCCCAAGCTTCCTCCCCCCTCGCGTGACTGCGAGGGGAAGGAGGCGTGG
CCACACGTCTAGACTAGCT3’. The XRE sites are in bold letters and the Hind III 
and Xba I restriction sites are in italic characters and underlined.  
 
CAT assays The chimeric construction pRNH25c containing the–1140/+80 region of 
CYP1A1 gene driving chloramphenicol acetyltransferase (CAT) gene expression was 
used. Cells in 6 well-plates were transiently transfected with 1 µg of pRNH25c using 
lipofectin (Life Technologies, France). The transfection was performed as specified 
by the supplier. 24h after the end of the transfection, cells were treated during 48 h 
with 200 µM WY-14643 or 1 µM 3-MC. CAT expression was then evaluated by the 
amount of CAT protein using the CAT Elisa System (Roche Diagnostic, France). 
A similar experiment was realized with a construct coding PPAR. Transfected 
cells with 1 µg of cDNA or untransfected cells were then either untreated or treated 
with 200 µM WY-14643 during 48 h. CYP1A1 mRNA level was determined as 
described above. 
Three independent experiments were at least realized in triplicate. 
 
Site-Directed mutagenesis of the CYP1A1 promoter The PPRE mutations of 
pRNH25c were introduced using the QuickChange site-directed mutagenesis kit 
(Stratagene, France) to obtain the pRNH25c(PPRE1), the pRNH25c(PPRE2) and 
the pRNH25c(PPRE1+2). The primers sense and antisense were used for 
mutagenesis. The primers sens were as follows (the PPRE core was underlined and 
bold letters represent mutated nucleotides compared to the wild type sequence (Wt)): 
Wt 1: 5’GGACGGGCCGCCTGACCTCTGCCCCCTAGAGGGATGTCG3’ 
PPRE1 muts : 5’GGACGGGCCGCCTGACCTCGATCCCCTAGAGGGATGTCG3’ 
Wt 2: 5’ GGCCTTCCGGCCCCGTGACCTCAGGGCTGGGGTCGCAGC 3’ 
PPRE2 mut-s : 5’GGCCTTCCGGCCCCGTGAATTCAGGGCTGGGGTCGCAGC3’ 
Presence of the mutations was verified by DNA sequencing. Cells were transfected 
by either the pRNH25c or pRNH25c(PPRE1) or pRNH25c(PPRE2) or 
pRNH25c(PPRE1+2) and after a 48 h-treatment with WY-14643 (200 µM) the CAT 
expression was evaluated as described above. 
 
In vitro translation and electromobility shift assays Electromobility shift assays 
were performed using PPAR and RXR prepared by in vitro translation using a 
coupled transcription-translation system (Promega, France). Proteins were incubated 
for 20 minutes at room temperature with 50.000 cpm of T4 polynucleotide kinase-
labeled oligonuclotides in 10 mM Tris (pH8.0), 100 mM KCl, 10% glycerol, 1 mM 
dithiothreitol, 1 g poly (dIdC) and 0.5 µg of salmon sperm. The mixture was then 
submitted to electrophoresis on a 4% polyacrylamide gel in 45 mM Tris Base, 45 mM 
boric acid, 1 mM EDTA. The following oligonucleotides were used either as 
radiolabeled probes or as competitors (the sense strand is shown, with core 
sequence underlined and mutation in bold face) : PPRE Cons, 5’-
CCGCCAAGCTTGCTCCGCCAGGTCACAGGTCACTAG ; CYP1A1-PPRE1, 5’-
GGACGGGCCGCCTGACCTCTGCCCCCTAGAGGGATGTCG; CYP1A1-PPRE2, 5’-
GGCCTTCCGGCCCCGTGACCTCAGGGCTGGGGTCGCAGC; CYP1A1-PPRE1 
mutant, 5’-GGACGGGCCGCCTGACCTCGATCCCCTAGAGGGATGTCG; CYP1A1-
PPRE2 mutant, 5’-GGCCTTCCGGCCCCGTGAATTCAGGGCTGGGGTCGCAGC . 
Anti-PPAR antibody (Santa Cruz Biotechnology) was used for the “supershift” 
assays. Autoradiography was carried out by exposing the dried gel to Kodac X-AR 
film. 
 
Chromatin ImmunoPrecipitation assay (ChIP) Confluent CaCo-2 cells (4 x 100mm 
dish) were treated with or without WY-14643 200 µM for 1 hour. Cells were then fixed 
with formaldehyde at 37°C for 15 min. The reaction was then stopped by addition of 
1ml 1 M glycine and incubation for 15 min at room temperature. Cells were 
harvested, and pooled. Soluble chromatin prepared with a chromatin immuno-
precipitation assay kit (Upstate Biotechnology Inc) was precleared for 1 h with 
salmon sperm DNA-BSA/Protein A–Sepharose. Precleared chromatin was then 
incubated for 16 h with 10 µg of anti-human PPAR antibodies (N-19 from Santa 
Cruz Biotechnology, or MIA-822 from Affinity BioReagents) or 10 µg of control mice 
IgG antibody (Sigma). Immune complexes were collected with 50 µl of Protein 
G-Sepharose (Santa Cruz Biotechnology) supplemented with salmon sperm DNA 
(200 µg/ml) and BSA (1 mg/ml) and purified according to manufacturer’s 
recommendations (Upstate Biotechnology Inc). Purified DNA samples (phenol-
chlorophorm-isoamyl alcohol and further on Qiagen columns) were used as template 
for PCR performed for 40 cycles (Pfx Taq DNA polymerase, Invitrogen). Similarly 
purified DNA fragments from the chromatin extracts (input) were used as control 
(PCR performed for 30 cycles). Cycling conditions were as follows: 3 min 
denaturation at 93°C, followed by 30 or 40 cycles of 30 s denaturation at 91°C, 30 s 
primer annealing at 55°C and 1 min of elongation at 72°C. Primers used for proximal 
CYP1A1 PPREs containing promoter region amplification were 
5’-GCCTCCGGTCCTTCACAC-3’ and 5’-CGCTACAGCCTACCAGGACT-3’ (-1000 to 
–413 upstream of the transcriptional start site), while primers used for distal CYP1A1 
promoter region (harboring no PPRE sites) were 5’-CACAACTTGCACTGCCCTTA-3’ 
and 5’-CCAACAGCTCATTGAGAACG-3’ (-4053 to -3780 upstream of the 
transcriptional start site). 
 
Statistical analysis Statistical analysis were performed using the Newman-Keuls 
test. Data were considered statistically significant at a p<0.05. Significant results 
were noted with * or ** or *** for a p<0.05, p<0.01 and p< 0.001 respectively. 
 
Results 
 
Induction of CYP1A1 gene by PPAR ligands 
CaCo-2 cells were treated during 6 h with increasing concentrations of 
WY-14643 (10-400 µM), or 50 µM BZF, or 50 µM CF, or 100 µM MEHP, or 200 µM 
TZD or 1 µM 3-MC. CYP1A1 mRNA was then evaluated by quantitative real-time 
(QRT-PCR) analysis. The results presented in Fig.1A show that TZD does not 
increase and even decreased CYP1A1 gene expression. In contrast, CYP1A1 mRNA 
levels increased after treatments with the PPAR ligands such as WY-14643 or BZF 
or CF or MEHP. The WY-14643 CYP1A1-mediated induction was dose dependent 
and reached the plateau at 200 µM (6-fold). 
The results presented in Figure 1B also show that CYP1A1 expression was 
induced after 200 µM WY-14643 treatment of various human cell lines other than 
CaCo-2 including HepG2 (hepatoma), in a primary culture of human keratinocytes 
and A549 (lung adenocarcinoma). However, the CYP1A1 inductions obtained in 
these cells were lower than in CaCo-2. 
 
Induction of CYP1A1 EROD activity by WY-14643  
The EROD activity was analyzed after treatment of CaCo-2 cells with 
increasing concentrations of WY-14643 (10-200 µM). The results, shown in Fig. 2, 
indicate that the CYP1A1 EROD activity was dose dependently induced by 
WY-14643 (10-fold at 200 µM) and that the induction obtained with 200 µM 
WY-14643 was similar to those obtained with 1 µM 3-MC (12.6-fold). 
 
WY-14643 did not stimulate the XRE sequence 
By means of CAT assay analysis, we investigated whether WY-14643, a 
potent PPAR ligand, was able to stimulate the XRE target sequences of AhR. Cells 
were treated either with 1 µM 3-MC, or 200 µM WY-14643 after transient transfection 
with a XRE-TKCAT construct. Figure 3A shows that 3-MC, a classic AhR ligand, 
activated CAT expression 2.1-fold, while WY-14643 did not increase CYP1A1 gene 
expression via the AhR signaling pathway. 
 
Transfection with PPAR cDNA increases the CYP1A1 induction by 
WY-14643 
To strengthen the implication of PPAR in CYP1A1 induction by WY-14643, 
PPAR transfected CaCo-2 cells were treated with WY-14643. Fig. 3 B shows that 
PPAR transfection doubled d CYP1A1 mRNA induction by 200 µM WY-14643 (10-
fold) as compared to cells receiving the reporter gene alone (6-fold). 
 
Two PPRE sequences located within the CYP1A1 gene promoter are 
involved in the CYP1A1 induction by WY-14613 
CYP1A1 promoter gene analysis, using Mathinspector (20), revealed that two 
putative PPRE sites are located within the promoter at positions –931/-919 
(CYP1A1PPRE1) and –531/-519 (CYP1A1PPRE2) respectively. 
To confirm that PPAR ligands were able to induce CYP1A1 mRNA by 
activation of its promoter, we transfected CaCo-2 cells with either the pRNH25c 
construct containing the wild type CYP1A1 promoter or with the pRNH25c construct 
where either the PPRE1 (pRNH25cPPRE1) or the PPRE2 (pRNH25cPPRE2) or 
the PPRE1+2 (pRNH25cPPRE1+2) sequences were mutated. Cells were then 
treated with either 200 µM WY-14643, or 1 µM 3-MC for 48 h. Figure 4 shows that 
WY-14643 and 3-MC efficiently induced the transactivation of the CYP1A1 wild type 
promoter pRNH25c (2.4-fold with 200 µM WY-14643 and 4.6-fold with 1 µM 3-MC). 
The mutation of one of the two CYP1A1 PPRE sites led to a decrease of CYP1A1 
promoter activation by WY-14643. Indeed, the induction of CAT expression was 
lower using the pRNH25cPPRE1 or pRNH25cPPRE2 constructs (1.6-fold and 1.4-
fold respectively) as compared to the pRNH25c construct (2.4-fold). When the two 
sites were mutated (pRNH25cPPRE1+2) the decrease of WY-14643 effect was 
higher (1.1-fold at 200 µM WY-14643). 
 
The two CYP1A1 PPRE sites were able to bind PPAR 
We first checked the binding of an in vitro translated PPAR-RXR heterodimer 
to the two CYP1A1 putative PPRE sequences by gel shift assay (Fig. 5). As 
expected, a specific retarded band was observed when PPAR and its partner RXR 
were incubated together with the target oligonucleotide (lane 5 and 11), but not when 
these receptors were incubated separately (lanes 3, 4 and 9, 10). We confirmed that 
the shift obtained using the CYP1A1 PPRE1 and PPRE2 was the consequence of 
the binding of PPAR usinga specific PPAR antibody which produced a super shift 
shown in lanes 6 and 12. 
In addition, the specific PPAR/RXR-PPRE complex was repressed in a 
dose-dependant manner when incubated in the presence of 10-fold (Fig. 6 lanes 7, 9, 
11) or 50-fold (lanes 6, 8, 10) excess of unlabeled consensus PPRE or unlabelled 
CYP1A1-PPRE1 or CYP1A1-PPRE2 sequences. 
In the same conditions, a 50-fold excess of mutated PPRE1 or PPRE2 
CYP1A1 sequences did not affect the binding of PPAR/RXR on the PPRE 
consensus core (Fig 6 lanes 12 and 13 respectively). A supershifted band appeared 
using a PPAR antibody (lane 14). 
These observations showed that the in vitro translated heterodimer 
PPAR/RXR binds to the two PPRE1 and PPRE2 sites within the CYP1A1 gene 
promoter. 
To strengthen our demonstration, ChIP analysis was performed using CaCo-2 
cells untreated or treated with 200 µM WY-14643 for 1 h. We showed (Figure 7) that 
the PPARRXR heterodimer binds to the PPRE sites located within the proximal 
CYP1A1 gene promoter. 
 
Discussion 
 
We characterized a new CYP1A1 regulation pathway involving the binding of 
PPAR transcription factor on two PPRE sequences located within the 5’ 
untranslated region of CYP1A1 gene. 
The effects of agonists of PPAR (WY-14643, CF, BZF and MEHP) and 
PPAR (TZD) on CYP1A1 mRNA expression levels were evaluated in Caco-2 cell 
line by real time QRT-PCR analysis. WY-14643 induced CYP1A1 mRNA in a dose 
dependent manner, up to 6-fold as soon as 200 µM. Similarly, CYP1A1 mRNA level 
was increased after 6h treatment with other PPAR ligands (CF, BZF, MEHP). The 
induction factors were lower than those observed with WY-14643, which is one of the 
most potent agonists of PPAR. These results confirmed that CYP1A1 is induced by 
different classes of PPAR ligands including the fibrates and phthalates. In contrast, 
TZD led to a marked decrease of CYP1A1 transcript. Such an antagonist regulatory 
effect of these two transcription factors (PPAR and PPAR) has already been 
described for some genes, such as VCAM-1 (21, 22). However, the repressive effect 
of PPAR on CYP1A1 expression remains to be clarified and is presently under 
investigation in our laboratory. Moreover, transfection of PPAR cDNA leads to a 
higher induction with WY-14643, strengthening the involvement in Caco-2 cell line of 
PPAR in CYP1A1 regulation. 
The CYP1A1 induction by PPAR was not restricted to CaCo-2 cells as similar 
results were obtained with HepG2 hepatoma cells, A549 lung adenocarcinoma cells, 
and primary cultures of human keratinocytes. The effect of PPAR ligands on 
CYP1A1 induction appears to be a general phenomenon and not restricted to colon 
cell lines. 
The induction of CYP1A1 mRNA by WY-14643 was associated with an 
increase of EROD activity. This induction of EROD activity was similar to that 
obtained with 1 µM 3-MC. Therefore, PPAR agonists may increase the genotoxic 
effect of procarcinogens bioactivated by CYP1A1, such as PAH or arylamines. Such 
a phenomenon was previously described with two peroxisome proliferators, silvex 
and di(2-ethylhexyl)phthalate, which enhance BAP-induced DNA adducts (16).  
To date, PPARligands belonging to the fibrates class have been widely used 
as hypolipidemic drugs, and have never been implicated in human carcinogenesis, 
although they are well known hepatocarcinogens in rodents. The lack of such a side 
effect in humans may be related to the poor expression of PPAR in liver. Our data 
suggest that expositions to environmental PPAR ligands, including fibrate and 
chemical compounds such as phthalates or chlorophenoxyacetic pesticides, may 
increase CYP1A1 extrahepatic expression. Therefore, cells harboring a higher 
CYP1A1 expression would have a greater susceptibility to the genotoxic effect of 
CYP1A1 bioactivated procancerogens.  
Since CYP1A1 is mainly regulated by the Ah receptor, it was logical to assume 
that WY-14643 could have a direct or indirect action on this transcription factor. 
However, using XRE-TK-CAT construct we showed that WY-14643 failed to activate 
XRE site, demonstrating that CYP1A1 induction by PPAR ligand did not involve 
AhR. 
Sequence analysis of CYP1A1 promoter revealed the presence of two putative 
PPRE sites. Indeed, treatment with WY-14643 increased CAT expression when cells 
were transiently transfected with pRNH25c harboring the wild-type CYP1A1 
promoter. The results obtained in Fig. 4 clearly demonstrate that the mutation of one 
PPRE site (PPRE1 or PPRE2) reduces the CAT induction while no induction 
occurred with pRNH25c (PPRE1+2). So, it appears that the two PPRE sites located 
within the promoter at positions –931/-919 (CYP1A1 PPRE1) and –531/-519 
(CYP1A1 PPRE2) respectively were necessary for the CYP1A1 induction by PPAR 
ligands.  
The direct role played by these 2 PPRE sites in the binding of PPAR 
transcription factor was evaluated first by EMSA. We found that even if the two sites 
diverge from the canonical DR1 sequence they are still able to bind PPAR with 
good efficiency . PPAR binding is no longer possible when mutations are introduced 
in these CYP1A1 PPRE sites. In order to demonstrate the in vivo relevance of these 
PPRE sites, we performed ChIP assays. We immunoprecipitated the human 
CYP1A1 gene promoter using two different anti-human PPAR antibodies, 
demonstrating that PPARRXR heterodimer binds in vivo on the CYP1A1 PPRE 
sites. We actually showed that with or without WY-14643 treatment, PPARRXR 
bound to the PPRE sites within the CYP1A1 promoter. This binding without any 
treatment has already been shown in CaCo-2 for the carnitine palmitoyltransferase II 
gene (23). Recently, with a ChIP assay performed on mouse liver extract, IJpenberg 
et al (24) did not observe any PPARRXR binding on PPRE site of malic enzyme 
gene in untreated mice but had to treat the animals with WY-14643 to visualize such 
a binding. Inversely, Jia et al (25) demonstrated in mouse liver extract, that PPAR 
RXR was already bound to PPRE site of L-PBE gene. Mouse treatment with 
WY-14643 seemed to increase this binding, but it is generally accepted that ChIP 
technology is qualitative but not quantitative. 
To date, it has not been clearly documented whether, without any ligand the 
PPARRXRheterodimer is unbound or bound to PPRE sites in an inactive 
conformation as  has been largely described for RAR (26). It seems that the binding 
of PPARRXR on PPRE sites in the presence or absence of PPAR ligands is 
dependent on the nature of the tissue, the cell type and the gene studied. 
The PPRE2 site appears to have an inverted orientation compared to a 
canonical consensus site while PPRE1 site displays a conventional orientation. 
Sequence alignment of CYP1A1 promoter (Figure 8) from various species 
demonstrates that PPRE1 and PPRE2 sites are highly conserved in human, rat and 
mouse species. Rat and mouse harbor the same PPRE1 and PPRE2 sequences and 
differ from humans in that they exhibit a unique base transition. Interestingly, the 
flanking regions are also conserved. Moreover, when sequence alignment was 
performed with CYP1A1 promoter from fish species, such as Anguilla japonica or 
Microgadus tomcod, we were unable to localize any PPRE sites, while several XRE 
sites are located within these promoters (data not shown). PPAR orthologs have 
already been described in fish species. Therefore the CYP1A1 regulation by PPAR 
occurred tardily in the evolution of species, contrary to the regulation of CYP1A1 by 
AhR. 
Until now, only the CYP4A, involved in fatty acid biotransformation, was known 
to be induced by PPAR ligands within the CYPs superfamily, (27). Since CYP1A1, 
largely concerned in procarcinogens activation, is also implicated in fatty acid 
metabolism (28), it was logical to find its expression regulated through PPAR. 
Moreover, CYP1A1 modification level could have a physiological impact in terms of 
fatty acid metabolite levels. 
 Until now, CYP1A1 was known to be expressed and induced by the 
transcription factor AhR. This is the first time that another strong CYP1A1 induction 
pathway, apart from AhR, has been described. We demonstrated that CYP1A1 was 
highly induced by PPAR via two PPRE sites within the promoter. The upregulation 
of CYP1A1 by PPAR ligands may be involved in human carcinogenesis, notably in 
colon through an increase of CYP1A1-bioactivated procancerogens present in diet, 
such as arylamines. 
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Figure 8 
Figure Legends 
 
Figure 1. (A): CYP1A1 mRNA levels in CaCo-2 cells. CYP1A1 mRNA was evaluated 
by QRT-PCR after cell treatment during 6 h with either WY-14643 (10, 30, 100, 200, 
400 µM), or 50 µM BZF, or 50 µM CF, or 100 µM MEHP; or 200 µM TZD; or 1 µM 3-
MC. C: control. **: p<0.01 compared with control. ***: p<0.001 compared with control. 
(B): Effect of WY-14643 on CYP1A1 expression in different cell lines. CYP1A1 
mRNA was evaluated by QRT-PCR after cell treatment during 6 h with 200 µM WY-
14643 or 1 µM 3-MC respectively in HepG2, keratinocytes, and A549. 
 
Figure 2. Evaluation of EROD activity. EROD activity was evaluated after CaCo-2 
cells treatment during 48 h with different WY-14643 concentrations (10, 30, 100, 200 
µM) or 1 µM 3-MC. C: control. **: p<0.01 compared with control. 
 
Figure 3. (A): Effect of WY-14643 on XRE activation. CaCo-2 cells were transfected 
with a construct where XRE drives CAT expression. After transfection, cells were 
treated 48 h with 200 µM WY-14643 or 1 µM 3-MC. CAT expression was evaluated 
using the CAT Elisa System. *: p<0.05 compared with control. (B): CaCo-2 cells were 
either untransfected or transfected with cDNA coding the PPAR and untreated or 
treated with 200 µM WY-14643 during 48 h. CYP1A1 mRNA level was then 
evaluated by Q-PCR as described in material and methods. ***: p<0.001 compared 
with cells which have been transfected with the empty vector and treated with 
WY-14643. 
 
Figure 4. Effect of PPRE mutations on CYP1A1 promoter activation. CaCo2 cells 
were transfected with the wild-type pRNH25c (A), or the pRNH25c(PPRE1) (B), or 
the pRNH25c(PPRE2) (C), or the pRNH25c(PPRE1+2) (D). Cells were then either 
untreated (C) or treated with 200 µM WY-14643 during 48 h. CAT expression was 
evaluated by CAT ELISA System. *: p<0.05 compared with control. ***: p<0.001 
compared with control. 
 
Fig 5. EMSA using CYP1A1 specific PPRE 1/2 sequences. RXR, PPAR or both 
were produced by reticulocytes and incubated with CYP1A1 PPRE1 (lanes 1-6), or 
CYP1A1 PPRE2 (lanes 7-12). Lanes 1 and 7: free probe; lanes 2 and 8: TNT; lanes 
3 and 9: RXRalone; lanes 4 and 10: PPAR alone; lanes 5 and 11: PPAR/RXR 
heterodimer; lanes 6 and 12: PPAR/RXR heterodimer + PPAR antibody. S: 
shifted band; SS: super shifted band; NS: unspecific band. 
 
Figure 6. Effect of unlabelled probes on EMSA. RXR, PPAR lanes 3, 4 or both 
lanes 5-14 were produced by reticulocytes and incubated with PPRE consensus 
sequence. Competition with unlabeled 50-fold or 10-fold PPRE consensus lanes 6, 7 
or CYP1A1 PPRE1 lanes 8, 9 or CYP1A1 PPRE2 lanes 10, 11 or 50-fold of mutated 
CYP1A1 PPRE 1 lane 12 or CYP1A1 PPRE2 lane 13 were realized. Lane 1 
corresponds to the free PPRE probe and lane 14 shows a super shift obtained with a 
specific PPAR antibody. S: shifted band; SS: super shifted band; NS: unspecific 
band. 
 
 
 
Figure 7. Chromatin immunoprecipitation assays of the CYP1A1 promoter in CaCo2 
cells.  CaCo2 cells were treated with or without 200 µM WY-14643 for 1 h. Soluble 
chromatin was immunoprecipitated with mice IgG (lanes 5-6), or antibodies against 
human PPAR (N19, lane 3-4; or MIA-822, lanes 7-8). Immunoprecipitates were 
analyzed by PCR with specific primers for the distal (-4053 to –3780) or proximal  
(-1000 to –413) CYP1A1 promoter as indicated. PCR was performed with total 
chromatin input (lanes 1-2). 
 
Figure 8. Sequence alignment of CYP1A1 promoter from human, rat and mouse. 
Sequence alignment was performed using LFASTA analysis 
(http://www.infobiogen.fr/services/analyseq/cgi-bin/lfastan_in.pl). Gene accession 
numbers are noted in brackets. PPRE sites are noted in bold capital letters, and 
mismatches are underlined. 
 
